What We're Reading: Page 391
Industry reads hand-picked by our editors
Nov 26, 2014
-
-
The Telegraph
Top UK fund manager to launch major new biotech fund in 2015
-
3 compounding pharmacies sue Express Scripts over blocked coverage
-
Lundbeck CEO resigns after serious conduct breaches
-
-
-
Novartis scientist who fabricated data fired and banned from receiving funding
-
-
In search of new opportunities, Bayer considers selling $2.5B diabetes unit
-
Nov 25, 2014
-
BioMarin makes $840M gamble, buys Prosensa and its orphan drugs
-
-
UK life sciences minister: Hospitals must aid in clinical trial process
-
-
Hep C wars heat up as AbbVie scores likely EU approval for Harvoni challenger
-
-
Merck, NewLink strike exclusive deal to scale up Ebola vaccine production
-
-
-
EU regulators weigh in on hotly debated testosterone, heart attack link
Nov 24, 2014
-
Sacré bleu! Sovaldi to cost 38.8% less in France than in US
-
-
Sanofi can't shake its diabetes business blues—and investors aren't happy
-
-
The 14 best-performing CEOs in biotech and pharma
-
Judge refuses to block Ranbaxy's generic competitors
-
-
EMA's updated conflict of interest policy reflects pragmatism, flexibility
-
-
Purdue joins burgeoning abuse-deterrent pain pill field with Hysingla approval
Nov 21, 2014
-
These execs are on Sanofi's CEO short list
-
-
US hep C, cancer, diabetes med costs drive global drug tab past $1 trillion mark
-
-
-
In massive transparency effort, feds push for failed clinical trial data reporting
-
-
Novartis aims to put more 'tech' in biotech
-
Goodbye Philly, hello Boston: Shire moves US HQ, 500 jobs
-
Another first: Gilead spends $125M on priority review voucher for mystery drug
Nov 20, 2014
-
-
HHS scraps regulations for 340B drug pricing program
-
-
India's Ranbaxy sues FDA for yanking Nexium, Valcyte generics approval
-
Plot twist: Controversial Merck cholesterol drugs Zetia, Vytorin work
-
Regeneron/Sanofi PCSK9 inhibitor could become cholesterol top dog
-
-
Rainmaker: Gilead's Harvoni approved in the EU
-
-
Has the price of developing drugs really doubled in the last 11 years?
Nov 19, 2014
-
HHS scraps regulations for 340B drug pricing program
-
-
Docs breathe sigh of relief as Actavis buyout ends Valeant-Allergan drama
-
-
Merck dances: Keytruda more than doubles PFS in some melanoma patients
-
-
How pharma has improved patients' access to drugs since 2012
-
-
FDA commish to talk drug safety at China regulatory chief confab
-
Nov 18, 2014
-
-
Cancer immunotherapy specialist Juno Therapeutics files for IPO
-
UPDATED: Actavis buys Allergan for $66 billion
-
-
-
Finally: FDA reverses course, OKs Sanofi's Lemtrada for MS
-
Another big win for Roche as Avastin nabs FDA ovarian cancer indication
-
-
-
EU's top drug regulator forced out by EMA panel
Previous
